Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.